Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $8,087,845 | $11,951,023 |
| General and administrative | 11,373,909 | 6,267,412 |
| Total operating expenses | 19,461,754 | 18,218,435 |
| Loss from operations | (19,461,754) | (18,218,435) |
| Other income: | ||
| Interest/investment income, net | 959,762 | 440,287 |
| Realized (loss)/gain on short-term investments | (9,867) | 62,952 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s G&A?
- Relmada Therapeutics, Inc. (RLMD) reported G&A of $11.37M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s G&A changed year-over-year?
- Relmada Therapeutics, Inc.'s G&A increased by 81.5% year-over-year, from $6.27M to $11.37M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s G&A?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s G&A has grown at a -2.1% compound annual growth rate (CAGR), from $35.08M to $32.22M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Relmada Therapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude